Figure 2.

Comparison of P-mTOR and P-S6 intensity and percent immunoreactive cells in primary nonmetastatic UCC (Non-met primary), primary UCC associated with metastases (Met primary), and paired lymph node metastases (LN met). A: 2 to 3+ P-mTOR immunoreactivity is present in the majority of UCC cases. B: Approximately one-third of all UCC cases demonstrate P-mTOR in at least 25% of tumor cells. C: 2 to 3+ P-S6 immunoreactivity is present in a lower percentage of UCC cases and shows a significant increase in lymph node metastases (P < 0.01, Fisher exact test); D, Similar to P-mTOR, of 2 to 3+ a large proportion of P-S6 expressing UCCs demonstrate expression in at least 25% of tumor cells, with a significant increase in expression in lymph node metastases (P = 0.01, Fisher exact test).